

# Luciano Potena

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1143444/publications.pdf>

Version: 2024-02-01

182  
papers

7,835  
citations

70961

41  
h-index

56606

83  
g-index

192  
all docs

192  
docs citations

192  
times ranked

8032  
citing authors

#	ARTICLE	IF	CITATIONS
1	Many heart transplant biopsies currently diagnosed as no rejection have mild molecular antibody-mediated rejection-related changes. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 334-344.	0.3	21
2	Pretransplant Right Ventricular Dysfunction Is Associated With Increased Mortality After Heart Transplantation: A Hard Inheritance to Overcome. <i>Journal of Cardiac Failure</i> , 2022, 28, 259-269.	0.7	9
3	Impact of prior sternotomy on survival and allograft function after heart transplantation: A single center matched analysis. <i>Journal of Cardiac Surgery</i> , 2022, , .	0.3	1
4	Impact of Predicted Heart Massâ€‘Based Donor-Recipient Size Matching on Transplant Outcomes. <i>Transplantation Proceedings</i> , 2022, 54, 774-781.	0.3	2
5	Candidacy for heart transplantation in adult congenital heart disease patients: A cohort study. <i>International Journal of Cardiology Congenital Heart Disease</i> , 2022, 8, 100363.	0.2	0
6	Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. <i>European Heart Journal</i> , 2022, 43, 2237-2246.	1.0	23
7	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. <i>Microorganisms</i> , 2022, 10, 1021.	1.6	13
8	Role of Quantitative Flow Ratio in Predicting Future Cardiac Allograft Vasculopathy in Heart Transplant Recipients. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, e011656.	1.4	1
9	Outcome of patients on heart transplant list treated with a continuous-flow left ventricular assist device: Insights from the TRans-Atlantic registry on VAd and TrAnspant (TRAVIATA). <i>International Journal of Cardiology</i> , 2021, 324, 122-130.	0.8	8
10	COVIDâ€‘19 and education: restructuring after the pandemic. <i>Transplant International</i> , 2021, 34, 220-223.	0.8	22
11	Longest reported support (7.5Â‘years) with postauricular type of Jarvik 2000 axial-flow left ventricular assist device. <i>Journal of Artificial Organs</i> , 2021, 24, 503-506.	0.4	1
12	Donorâ€‘derived human herpesvirus 8 infection with Kaposi sarcoma and Kaposi sarcoma inflammatory cytokine syndrome in a heart transplant recipient: A case report. <i>Transplant Infectious Disease</i> , 2021, 23, e13609.	0.7	3
13	miR-21 antagonism reprograms macrophage metabolism and abrogates chronic allograft vasculopathy. <i>American Journal of Transplantation</i> , 2021, 21, 3280-3295.	2.6	14
14	Postâ€‘discharge arrhythmic risk stratification of patients with acute myocarditis and lifeâ€‘threatening ventricular tachyarrhythmias. <i>European Journal of Heart Failure</i> , 2021, 23, 2045-2054.	2.9	17
15	Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 3391-3409.	2.0	11
16	Guidance on the management of left ventricular assist device <sc>(LVAD)</sc> supported patients for the nonâ€‘<sc>LVAD</sc> specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021, 23, 1597-1609.	2.9	20
17	Covid-19 in recipients of heart and lung transplantation: Learning from experience. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 948-950.	0.3	5
18	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€‘supported patients for the nonâ€‘left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	1.4	7

#	ARTICLE	IF	CITATIONS
19	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	1.4	5
20	An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. Transplantation Reviews, 2021, 36, 100655.	1.2	15
21	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	1.4	10
22	Development of post-transplant risk scores: Dancing to off-key tunes. Journal of Heart and Lung Transplantation, 2021, 40, 1668-1669.	0.3	0
23	Advanced Heart Failure: From Pathophysiology to Clinical Management. Heart Failure Clinics, 2021, 17, i.	1.0	0
24	Management of Advanced Heart Failure: The Science of Uncertainty and the Art of Probability. Heart Failure Clinics, 2021, 17, xv-xvi.	1.0	0
25	Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAViATA. International Journal of Cardiology, 2021, 340, 26-33.	0.8	4
26	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric lung transplantation report " 2021; Focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1023-1034.	0.3	24
27	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report " 2021; Focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1035-1049.	0.3	132
28	Right Heart Catheterization in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 647-660.	1.0	5
29	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report " 2021; Focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1060-1072.	0.3	233
30	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth pediatric heart transplantation report " 2021; focus on recipient characteristics. Journal of Heart and Lung Transplantation, 2021, 40, 1050-1059.	0.3	32
31	Pediatric Restrictive Cardiomyopathies. Frontiers in Pediatrics, 2021, 9, 745365.	0.9	12
32	Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. Journal of Nephrology, 2020, 33, 69-82.	0.9	8
33	Soluble HLA-G pre-transplant levels to identify the risk for development of infection in heart transplant recipients. Human Immunology, 2020, 81, 147-150.	1.2	7
34	MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. Journal of Heart and Lung Transplantation, 2020, 39, 1353-1362.	0.3	75
35	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult lung transplantation report " 2020; focus on deceased donor characteristics. Journal of Heart and Lung Transplantation, 2020, 39, 1016-1027.	0.3	60
36	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report " 2020; focus on deceased donor characteristics. Journal of Heart and Lung Transplantation, 2020, 39, 1003-1015.	0.3	150

#	ARTICLE	IF	CITATIONS
37	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-third pediatric lung transplantation report "2020; focus on deceased donor characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1038-1049.	0.3	12
38	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 23rd pediatric heart transplantation report"2020; focus on deceased donor characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1028-1037.	0.3	73
39	Donor risk analysis and validation in heart transplants: a single-centre experience. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 860-867.	0.5	6
40	The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1367-1376.	0.9	7
41	Postoperative outcomes following rehabilitation in patients with left ventricular assist devices. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	5
42	Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 619-626.	0.3	31
43	Management of heart transplant candidates in the time of COVID-19 pandemic: Looking for answers. <i>American Journal of Transplantation</i> , 2020, 20, 2956-2957.	2.6	2
44	Viral genome search in myocardium of patients with fulminant myocarditis. <i>European Journal of Heart Failure</i> , 2020, 22, 1277-1280.	2.9	19
45	Manifestations of health anxiety in patients with heart transplant. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 364-369.	0.8	8
46	Heart rate reserve during dipyridamole stress test applied to potential heart donors in brain death. <i>Minerva Cardioangiologica</i> , 2020, 68, 249-257.	1.2	5
47	Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 299-311.	1.2	148
48	Heart Transplant and Hepato-Renal Dysfunction: The Model of End-Stage Liver Disease Excluding International Normalized Ratio as a Predictor of Postoperative Outcomes. <i>Transplantation Proceedings</i> , 2019, 51, 2962-2966.	0.3	11
49	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report "2019; focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1056-1066.	0.3	597
50	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric lung and heart-lung transplantation report"2019; Focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1015-1027.	0.3	97
51	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-second pediatric heart transplantation report "2019; Focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1028-1041.	0.3	159
52	The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart"lung transplantation Report"2019; Focus theme: Donor and recipient size match. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1042-1055.	0.3	711
53	Prevalence of Medication Nonadherence to Co-medication Compared to Immunosuppressants in Heart Transplant Recipients: Findings From the International Cross-sectional BRIGHT Study. <i>Clinical Therapeutics</i> , 2019, 41, 130-136.	1.1	11
54	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2019, 291, 77-82.	0.8	22

#	ARTICLE	IF	CITATIONS
55	Liver and kidney function in refractory heart failure: The narrow gate to achieve post-transplant survival. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 115-116.	0.7	1
56	An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 636-646.	0.3	43
57	Differences in cardiac phenotype and natural history of laminopathies with and without neuromuscular onset. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 263.	1.2	12
58	Does the antibody mediated rejection grading scale have prognostic prediction? Yes, but the picture is still blurry. <i>Current Opinion in Organ Transplantation</i> , 2019, 24, 265-270.	0.8	2
59	Coronary artery disease in heart transplantation: new concepts for an old disease. <i>Transplant International</i> , 2018, 31, 787-827.	0.8	13
60	The management of antibodies in heart transplantation: An ISHLT consensus document. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 537-547.	0.3	114
61	Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	32
62	Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients. <i>Transplantation</i> , 2018, 102, 493-501.	0.5	28
63	Molecular Assessment of Heart Transplant Biopsies. <i>Transplantation</i> , 2018, 102, S62-S63.	0.5	3
64	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	2.9	555
65	Pregnancy and Heart Transplantation. <i>Transplantation</i> , 2018, 102, 1411-1412.	0.5	2
66	Validating the INTERHEART Classifiers for Molecular Diagnosis of Rejection in 558 New Endomyocardial Biopsies. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S303-S304.	0.3	1
67	Complications of Cardiac Transplantation. <i>Current Cardiology Reports</i> , 2018, 20, 73.	1.3	39
68	Quantiferon Monitor Assay Identifies Over-Immunosuppressed Patients with Adverse Outcomes After Heart Transplantation: Towards the Definition of a Phenotype of Immune Frailty. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S19-S20.	0.3	2
69	Exploring the cardiac response to injury in heart transplant biopsies. <i>JCI Insight</i> , 2018, 3, .	2.3	43
70	P2X7R mutation disrupts the NLRP3-mediated Th program and predicts poor cardiac allograft outcomes. <i>Journal of Clinical Investigation</i> , 2018, 128, 3490-3503.	3.9	31
71	Antibody-mediated rejection in heart transplantation. <i>Current Opinion in Organ Transplantation</i> , 2017, 22, 207-214.	0.8	19
72	Heart allograft preservation. <i>Current Opinion in Cardiology</i> , 2017, 32, 292-300.	0.8	12

#	ARTICLE	IF	CITATIONS
73	The Conundrum of Equitable Organ Allocation in Heart Transplantation. <i>Transplantation</i> , 2017, 101, 1969-1970.	0.5	3
74	Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation. <i>Transplantation</i> , 2017, 101, 1935-1944.	0.5	34
75	Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1217-1225.	0.3	66
76	The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. <i>American Journal of Transplantation</i> , 2017, 17, 42-53.	2.6	55
77	Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1192-1200.	0.3	107
78	Antithymocyte Globulins in Heart Transplantation. <i>Transplantation</i> , 2016, 100, 483-484.	0.5	0
79	Cytomegalovirus Immunoglobulin After Thoracic Transplantation. <i>Transplantation</i> , 2016, 100, S1-S4.	0.5	19
80	Cardiac Transplantation and the Contribution of Pathology. , 2016, , 3-10.		0
81	Donor Selection Criteria: Clinical and Pathological Insights. , 2016, , 115-135.		1
82	Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation. <i>Transplantation</i> , 2016, 100, S19-S26.	0.5	24
83	The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2016, 100, 39-53.	0.5	105
84	Cholesterol efflux capacity: A weak player in the complex plot of cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1286-1288.	0.3	2
85	Current Perspectives on Cytomegalovirus in Heart Transplantation. <i>Current Transplantation Reports</i> , 2016, 3, 358-366.	0.9	0
86	Unraveling the Process of the Dying Heart. <i>Transplantation</i> , 2016, 100, 2521-2523.	0.5	1
87	Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1611-1622.	0.9	27
88	Risk Stratification to Improve Transplant Benefit in Older Candidates: Are All Comorbidities Created Equal?. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S27-S28.	0.3	0
89	Quantiferon Monitor: A Novel Assay for Prediction of Infectious Risk in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S106.	0.3	2
90	Outcomes of Heart Transplantation for Transthyretin-Related Amyloid Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S63-S64.	0.3	2

#	ARTICLE	IF	CITATIONS
91	The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1-23.	0.3	1,096
92	Graft Failure/Dysfunction: Clinical Issues and Role of Endomyocardial Biopsy. , 2016, , 155-169.		1
93	Malignancies After Heart Transplantation. , 2016, , 329-352.		0
94	Design and Implementation of the International Genetics and Translational Research in Transplantation Network. <i>Transplantation</i> , 2015, 99, 2401-2412.	0.5	60
95	mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?. <i>Transplantation Reviews</i> , 2015, 29, 93-102.	1.2	47
96	Inflammatory Cell Burden and Phenotype in Endomyocardial Biopsies With Antibody-Mediated Rejection (AMR): A Multicenter Pilot Study From the AECVP. <i>American Journal of Transplantation</i> , 2015, 15, 526-534.	2.6	26
97	Influence of Angiotensin-Type1-Receptor Antibodies in Chronic Vascular Injury on Heart Transplant Patients. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S99-S100.	0.3	1
98	Correlation Between Lipid Levels and Cardiovascular Events in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S60.	0.3	0
99	Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Outcome, Treatment Strategies and Analysis of Risk Factors. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S192-S193.	0.3	0
100	Everolimus and Valganciclovir Prophylaxis: How to Chase CMV But Not the Patient: Insights From PROTECT Randomized Study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, S305.	0.3	2
101	Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1146-1153.	0.3	45
102	The International Society for Heart and Lung Transplantation Registries in the Era of Big Data With Global Reach. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1225-1232.	0.3	11
103	Novel therapeutic and diagnostic management of heart transplant patients. <i>Heart, Lung and Vessels</i> , 2015, 7, 198-207.	0.4	1
104	Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 24-32.	1.1	16
105	Medium-term outcome of recipients of marginal donor hearts selected with new stress-echocardiographic techniques over standard criteria. <i>Cardiovascular Ultrasound</i> , 2014, 12, 20.	0.5	20
106	Identification of ATTR-Related Subclinical Amyloidosis With <sup>99m</sup> Tc-DPD Scintigraphy. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 531-532.	2.3	91
107	Reconstitution of CMV-Specific Immunity After Heart Transplantation May Guide Customization of Immunosuppressive and Antiviral Strategies: A Prospective Randomized Study. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S154-S155.	0.3	0
108	Prognostic stratification and treatment of cardiac light chain amyloidosis: A narrow path in the jungle. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 136-138.	0.3	3



#	ARTICLE	IF	CITATIONS
109	Epidemiology, Mortality and Risk Factors of Primary and Secondary Graft Failure According with ISHLT Consensus Criteria. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S173.	0.3	1
110	Inflammatory Cell Burden and Phenotype in Endomyocardial Biopsies from Patients with Antibody-Mediated Rejection (AMR) – An AECVP Multicenter Study. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S19.	0.3	1
111	Clinical and Prognostic Correlates of pAMR Grading in Patients with Suspect Antibody Mediated Rejection. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S103.	0.3	0
112	Extracorporeal Membrane Oxygenation Support System as Bridge to Solution in Refractory Cardiogenic Shock. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S186.	0.3	8
113	Late Changes in Maximal Intimal Thickness after Heart Transplant: Prognostic Implications and Risk Factors. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, S33-S34.	0.3	0
114	Everolimus immunosuppression in de novo heart transplant recipients: What does the evidence tell us now?. <i>Transplantation Reviews</i> , 2013, 27, 76-84.	1.2	28
115	Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. <i>Transplant Infectious Disease</i> , 2013, 15, 150-162.	0.7	58
116	Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. <i>Reviews in Medical Virology</i> , 2013, 23, 97-125.	3.9	60
117	Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial. <i>American Journal of Transplantation</i> , 2013, 13, 1203-1216.	2.6	201
118	Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice. <i>American Journal of Transplantation</i> , 2013, 13, 1217-1226.	2.6	62
119	Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies. <i>Journal of Transplantation</i> , 2013, 2013, 1-6.	0.3	13
120	New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 99-105.	1.4	36
121	24-Month Safety and Efficacy of Concentration Controlled Everolimus with Reduced Cyclosporine Versus Mycophenolate Mofetil in 721 De Novo Heart Transplant Recipients: Results from the A2310 Study. <i>Transplantation</i> , 2012, 94, 127.	0.5	0
122	Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: Long-term follow-up of the SHIRAKISS randomized, prospective study. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 565-570.	0.3	56
123	169 Interplay between Pulmonary Hypertension and Donor-Recipient Matching in the Risk for Early Graft Failure after Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S65-S66.	0.3	0
124	649 Study Design and Preliminary Results of the Italian Everolimus Registry CERTIC. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S223-S224.	0.3	1
125	171 Lower Incidence of Viral Infections with Everolimus Versus MMF in De Novo Heart Transplant Recipients: 12 Month Analysis of a Randomized Multicenter Study. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, S63-S64.	0.3	0
126	Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1305-1311.	0.3	20



#	ARTICLE	IF	CITATIONS
127	Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions. <i>Clinical Transplantation</i> , 2011, 25, E475-86.	0.8	24
128	Changes in exercise capacity induced by heart transplantation: prognostic and therapeutic implications. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2011, 21, 519-525.	1.3	8
129	Update and Review: State-of-the-Art Management of Cytomegalovirus Infection and Disease Following Thoracic Organ Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, S1-S17.	0.3	83
130	Identification and Classification of Acute Cardiac Rejection by Intragraft Transcriptional Profiling. <i>Circulation</i> , 2011, 123, 2236-2243.	1.6	30
131	Cyclosporine Lowering With Everolimus or Mycophenolate to Preserve Renal Function in Heart Recipients: A Randomized Study. <i>Transplantation</i> , 2010, 89, 263-265.	0.5	29
132	Psychological Predictors of Mortality in Heart Transplanted Patients: A Prospective, 6-Year Follow-Up Study. <i>Transplantation</i> , 2010, 89, 879-886.	0.5	43
133	474: Interaction of CMV Prophylaxis and Pre-Emptive Strategies with Immunosuppressive Therapy: Potential Antiviral Effect of Everolimus. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, S155-S156.	0.3	1
134	Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. <i>Basic Research in Cardiology</i> , 2009, 104, 427-434.	2.5	28
135	34: C4d Detection and Outcome in Long-Term Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, S76-S77.	0.3	0
136	Prophylaxis Versus Preemptive Anti-cytomegalovirus Approach for Prevention of Allograft Vasculopathy in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 461-467.	0.3	83
137	Prophylaxis Versus Preemptive Therapy for Prevention of the Consequences of Cytomegalovirus Infection in Transplant Recipients: A Still Unresolved Issue. <i>Transplantation</i> , 2009, 87, 305-306.	0.5	6
138	Age and heart transplantation: results from a heart failure management unit. <i>Clinical Transplantation</i> , 2008, 22, 150-155.	0.8	3
139	Heart Transplantation in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2008, 101, 387-392.	0.7	70
140	186: Role of NT-proBNP and Right Heart Catheterization Measurements in Predicting Outcome of Patients Referred for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, S127-S128.	0.3	0
141	Safety and Efficacy of Ezetimibe With Low Doses of Simvastatin in Heart Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 685-688.	0.3	18
142	Comparison of Polymerase Chain Reaction of Polymorphonuclear Leukocytes and Plasma Identifies Patients Who Control Cytomegalovirus Infection after Hematopoietic Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2008, 47, 535-539.	2.9	0
143	Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 4121-4121.	1.8	0
144	Reproducibility of IVUS measurements in heart transplant recipients: Increased quality of data by using dedicated software for image analysis. , 2008, , .		2

#	ARTICLE	IF	CITATIONS
145	Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus. <i>Transplantation</i> , 2008, 85, 827-833.	0.5	20
146	Long-Term Effect of Folic Acid Therapy in Heart Transplant Recipients: Follow-Up Analysis of a Randomized Study. <i>Transplantation</i> , 2008, 85, 1146-1150.	0.5	7
147	Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1804-1810.	1.8	28
148	Cytomegalovirus-associated allograft rejection in heart transplant patients. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 425-431.	1.3	85
149	Changes in Coronary Arterial Dimensions Early After Cardiac Transplantation. <i>Transplantation</i> , 2007, 83, 700-705.	0.5	44
150	Prevalence of Substance-Related Disorders in Heart Transplantation Candidates. <i>Transplantation Proceedings</i> , 2007, 39, 1970-1972.	0.3	12
151	Interplay Between Systemic Inflammation and Markers of Insulin Resistance in Cardiovascular Prognosis After Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 324-330.	0.3	23
152	Cardiac Allograft Vasculopathy and Insulin Resistance—Hope for New Therapeutic Targets. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 965-981.	1.2	13
153	Potential of Medical Treatment, Device Therapy, and Conventional Surgery in Patients Referred for Heart Transplantation. <i>Journal of Cardiac Surgery</i> , 2007, 22, 456-458.	0.3	0
154	Static and Dynamic Predictors of Adverse Events in Patients with Intermediate Cardiopulmonary Capacity Referred for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 85-89.	0.3	2
155	273. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, S138-S139.	0.3	0
156	Prognostic Stratification of Women With Chronic Heart Failure Referred for Heart Transplantation: Relevance of Gender as Compared With Gender-related Characteristics. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 648-652.	0.3	7
157	Prognostic Implications of Serial Assessments of Pulmonary Hypertension in Severe Chronic Heart Failure. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1241-1246.	0.3	155
158	Long-Term Safety and Effectiveness of Statins for Heart Transplant Recipients in Routine Clinical Practice. <i>Transplantation Proceedings</i> , 2006, 38, 1507-1510.	0.3	27
159	Peripheral Blood Leukocyte Counts in Cytomegalovirus Infected Heart Transplant Patients: Impact of Acute Disease Versus Subclinical Infection. <i>Transplantation</i> , 2006, 82, 1419-1424.	0.5	5
160	Acute Rejection and Cardiac Allograft Vascular Disease Is Reduced by Suppression of Subclinical Cytomegalovirus Infection. <i>Transplantation</i> , 2006, 82, 398-405.	0.5	128
161	Relevance of cardioverter defibrillators for the prevention of sudden cardiac death on the timing of heart transplantation. <i>Clinical Transplantation</i> , 2006, 20, 684-688.	0.8	8
162	T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease. <i>Circulation</i> , 2006, 114, 1608-1615.	1.6	89

#	ARTICLE	IF	CITATIONS
163	Impaired Dendritic Cell Immunophenotype and Function in Heart Transplant Patients Undergoing Active Cytomegalovirus Infection. <i>Transplantation</i> , 2005, 79, 219-227.	0.5	16
164	Homocysteine-Lowering Therapy and Early Progression of Transplant Vasculopathy: A Prospective, Randomized, IVUS-Based Study. <i>American Journal of Transplantation</i> , 2005, 5, 2258-2264.	2.6	16
165	Nitrates and Angina: an insight into arterial and venular involvement in blood flow regulation. <i>Physica Medica</i> , 2005, 21, 81-85.	0.4	1
166	Safety and Efficacy of Two Types of Influenza Vaccination in Heart Transplant Recipients: A Prospective Randomised Controlled Study. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 588-592.	0.3	69
167	Aggressive anti-cytomegalovirus prophylaxis and acute rejection in high risk patients: Beat the virus and prevent the rejection. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, S117-S118.	0.3	0
168	Relationship between psychiatric disorders and physical status during the course of a heart transplantation program: a prospective, longitudinal study. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005, 6, 900-3.	0.1	1
169	Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells. <i>Circulation</i> , 2004, 109, 532-536.	1.6	85
170	Implications of cardiac resynchronization therapy and prophylactic defibrillator implantation among patients eligible for heart transplantation. <i>American Journal of Cardiology</i> , 2004, 93, 371-373.	0.7	14
171	Cytomegalovirus and Heart Transplant Atherosclerosis: A Likely Guilt Hidden by Weak Proofs. <i>Transplantation</i> , 2004, 78, 631.	0.5	2
172	Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. <i>American Heart Journal</i> , 2003, 146, 298-303.	1.2	34
173	Distance between Patients' Subjective Perceptions and Objectively Evaluated Disease Severity in Chronic Heart Failure. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 166-170.	4.0	32
174	Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. <i>Transplantation</i> , 2003, 75, 839-843.	0.5	59
175	Hospitalization for congestive heart failure: is it still a cardiology business?. <i>European Journal of Heart Failure</i> , 2002, 4, 99-104.	2.9	19
176	Accelerated QRS widening as an independent predictor of cardiac death or of the need for heart transplantation in patients with congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 899-901.	0.3	54
177	Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease. <i>Clinical Nutrition</i> , 2002, 21, 245-248.	2.3	5
178	Time course and determinants of graft vascular remodelling in heart transplant recipients: a prospective study. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 195.	0.3	0
179	Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C>T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 1245-1251.	0.3	9
180	Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 710-715.	0.3	43

#	ARTICLE	IF	CITATIONS
181	Delayed Acquisition of High Avidity Anti-Cytomegalovirus Antibody Is Correlated with Prolonged Antigenemia in Solid Organ Transplant Recipients. <i>Journal of Infectious Diseases</i> , 1998, 178, 1145-1149.	1.9	36
182	Cytomegalovirus Management in Solid Organ Transplant Recipients: A Pre-COVID-19 Survey From the Working Group of the European Society for Organ Transplantation. <i>Transplant International</i> , 0, 35, .	0.8	12